Incidence and co-morbidity in survivors of the EpiBel cohort compared to other cohorts described in literature. Survival rate was calculated based on the total number of admitted infants
| EpiBel | EpiCure6 | Larsson7 | De Jonge8 | Hussain9 | Bardin10 | |
|---|---|---|---|---|---|---|
| NA = not available; ROP = retinopathy of prematurity; CLD = chronic lung disease; CNS = central nervous system. | ||||||
| Gestational age (weeks) | ⩽26 | <26 | ⩽26 | ⩽26 | ⩽26 | ⩽26 |
| Survival rate | 58% | 39% | NA | 68% | NA | 62.5% |
| Number of survivors | 175 | 314 | 57 | 157 | 243 | 115 |
| Major (⩾stage 3) ROP | 25.5% | NA | 35% | 26.8% | 14.4% | 20.8% |
| Threshold ROP | 19.8% | 14% | NA | NA | 3.7% | NA |
| Associated morbidity | ||||||
| CLD | 10.6% | 9.8% | NA | NA | NA | NA |
| CNS at discharge | 3% | 6.2% | NA | 3.2% | NA | NA |
| Isolated | 8% | 4.7% | NA | NA | NA | NA |